Profile data is unavailable for this security.
About the company
Bioceltix SA is a Poland-based biopharmaceutical company, which operates in the field of veterinary medicine. The Company deal with the development of candidates for veterinary medicinal products based on the immunomodulatory properties of mesenchymal stem cells used as the active substance of the drug. Entity's products are intended for the treatment of companion animals. The Company carry out research and development works, which enable clinical trials and full registration of medicinal products in the European Medicines Agency, as is the case with medicines and drugs administered to humans.
- Revenue in PLN (TTM)0.00
- Net income in PLN-14.93m
- Incorporated2018
- Employees41.00
- LocationBioceltix SAul. Bierutowska 57-59, bud. IIIWROCLAW 51-317PolandPOL
- Phone+48 718808771
- Fax+48 717345509
- Websitehttps://bioceltix.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Meilleure Health Intrntnl Indu Grp Ltd | 17.29m | 17.78m | 441.56m | 49.00 | 24.79 | 0.7991 | -- | 25.54 | 0.0096 | 0.0096 | 0.0093 | 0.2978 | 0.0223 | 0.0363 | 0.9608 | 828,173.90 | 2.28 | 2.74 | 2.60 | 3.02 | 72.64 | 47.18 | 102.27 | 28.59 | 2.39 | -- | 0.2211 | 41.83 | -60.81 | -26.41 | -20.45 | -- | -1.03 | -- |
| Recce Pharmaceuticals Ltd | 19.34m | -53.80m | 442.86m | -- | -- | -- | -- | 22.90 | -0.0899 | -0.0899 | 0.0325 | -0.0106 | 0.8203 | -- | 25.91 | -- | -228.15 | -150.15 | -- | -318.01 | -- | -- | -278.12 | -340.57 | -- | -17.98 | 1.49 | -- | 47.14 | 46.35 | -21.33 | -- | 34.71 | -- |
| Auxly Cannabis Group Inc | 382.21m | 118.69m | 447.36m | 388.00 | 4.07 | 0.977 | 3.05 | 1.17 | 0.0307 | 0.0307 | 0.1019 | 0.1279 | 0.5401 | 1.75 | 6.63 | 376,275.80 | 16.77 | -18.35 | 22.80 | -23.05 | 52.00 | 26.34 | 31.05 | -72.02 | 1.05 | 3.07 | 0.2767 | -- | 21.02 | 71.06 | 63.27 | -- | -40.74 | -- |
| Formosa Pharmaceuticals Inc | 1.37m | -8.36m | 458.97m | -- | -- | 2.70 | -- | 335.12 | -0.5083 | -0.5083 | 0.0818 | 10.00 | 0.0057 | -- | 4.64 | -- | -3.49 | -30.53 | -3.80 | -33.88 | 4.52 | -- | -610.20 | -758.21 | 9.55 | -- | 0.0161 | -- | 359.89 | 163.52 | 37.56 | -- | 103.21 | -- |
| Astena Holdings Co Ltd | 1.44bn | 50.26m | 459.01m | 1.42k | 8.96 | 0.7239 | 4.34 | 0.3183 | 54.22 | 54.22 | 1,555.72 | 671.41 | 0.8961 | 3.62 | 2.88 | -- | 3.11 | 0.9587 | 6.26 | 1.76 | 34.85 | 30.40 | 3.47 | 1.05 | 0.9228 | -- | 0.4519 | 114.25 | 8.19 | -0.808 | 186.60 | 1.97 | 12.61 | 2.38 |
| Bioceltix SA | 0.00 | -14.93m | 461.94m | 41.00 | -- | 15.23 | -- | -- | -2.95 | -2.95 | 0.00 | 5.48 | 0.00 | 84.09 | -- | 0.00 | -40.05 | -79.12 | -43.34 | -96.10 | -- | -41,525.74 | -- | -409,752.20 | 8.82 | -- | 0.0148 | -- | -- | -- | -8.84 | -- | 6.21 | -- |
| Whitehawk Therapeutics Inc | 51.03m | -55.41m | 469.85m | 22.00 | 20.69 | 0.8426 | -- | 9.21 | 0.1358 | 0.1358 | 0.2802 | 3.33 | 0.1138 | 0.5669 | 4.40 | 359,600.00 | -12.36 | -52.97 | -13.76 | -60.63 | 89.22 | -- | -108.58 | -372.67 | 16.76 | -- | 0.00 | -- | 6.69 | -- | 3.15 | -- | 47.49 | -- |
| Bajaj Healthcare Ltd | 239.87m | 20.49m | 470.17m | 904.00 | 23.54 | -- | 15.05 | 1.96 | 16.15 | 15.36 | 188.83 | -- | -- | -- | -- | 6,774,850.00 | -- | 7.07 | -- | 13.07 | 46.31 | 37.17 | 8.54 | 8.22 | -- | 2.92 | -- | 5.83 | 14.61 | 5.76 | 399.64 | 11.21 | -12.65 | -- |
Data as of Feb 10 2026. Currency figures normalised to Bioceltix SA's reporting currency: Polish New Zloty PLN
4.76%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 30 Jun 2025 | 144.70k | 2.62% |
| TFI PZU SAas of 30 Jun 2025 | 73.62k | 1.33% |
| AgioFunds TFI SAas of 30 Dec 2025 | 27.50k | 0.50% |
| Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SAas of 30 Jun 2025 | 12.00k | 0.22% |
| SSgA Funds Management, Inc.as of 08 Jan 2026 | 3.01k | 0.05% |
| Rockbridge TFIas of 30 Jun 2025 | 2.70k | 0.05% |
More ▼
Data from 30 Jun 2025 - 08 Jan 2026Source: FactSet Research Systems Inc.
